Phase II study of XELOX as perioperative chemotherapy for locally advanced rectal cancer

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2012
INTERVENTION: Periooerative chemotherapy with XELOX for locally advanced rectal cancer CONDITION: Locally advanced rectal cancer PRIMARY OUTCOME: 3‐y relapse‐free survival rate SECONDARY OUTCOME: Overall survival rate, Local recurrence‐free survival rate, Pathological complete response rate, Safety INCLUSION CRITERIA: (1)Writen informed consent (2)Histologically proven adenocarcinoma of the rectum (3)Clinical confirmed locally advanced rectal cancer (4)Without distant metastases (M0) (5)Age: 20‐80 years (6)Performance status (PS) 0‐1 (7)Alife expectancy greater than 12 weeks (8)Without prior radiotherapy for the pelvis (9)Adequate organ function
Epistemonikos ID: 9cbb6df8052bd9ea05158586222862aa8e1a2e6a
First added on: Aug 22, 2024